Poseida Therapeutics, Inc. (NASDAQ:PSTX – Free Report) – Research analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Poseida Therapeutics in a research report issued on Tuesday, July 11th. Cantor Fitzgerald analyst J. Kim expects that the company will post earnings per share of ($2.53) for the year. The consensus estimate for Poseida Therapeutics’ current full-year earnings is ($1.70) per share.
Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). Poseida Therapeutics had a negative return on equity of 28.56% and a negative net margin of 32.13%. The business had revenue of $10.34 million for the quarter, compared to analyst estimates of $10.00 million.
Poseida Therapeutics Stock Up 0.5 %
Shares of NASDAQ PSTX opened at $1.95 on Wednesday. The stock has a market cap of $169.22 million, a PE ratio of -3.20 and a beta of 0.12. The business has a fifty day moving average of $2.40 and a two-hundred day moving average of $4.18. Poseida Therapeutics has a 52-week low of $1.54 and a 52-week high of $8.82. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.35 and a current ratio of 5.35.
Institutional Investors Weigh In On Poseida Therapeutics
Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC grew its holdings in shares of Poseida Therapeutics by 29.4% during the 2nd quarter. SG Americas Securities LLC now owns 31,016 shares of the company’s stock worth $55,000 after purchasing an additional 7,056 shares in the last quarter. Callan Capital LLC boosted its position in shares of Poseida Therapeutics by 9.1% during the first quarter. Callan Capital LLC now owns 68,007 shares of the company’s stock valued at $209,000 after buying an additional 5,660 shares during the last quarter. Susquehanna International Group LLP lifted its holdings in Poseida Therapeutics by 139.5% during the first quarter. Susquehanna International Group LLP now owns 651,394 shares of the company’s stock worth $2,006,000 after acquiring an additional 379,418 shares during the period. Jane Street Group LLC raised its stake in shares of Poseida Therapeutics by 259.9% in the first quarter. Jane Street Group LLC now owns 253,169 shares of the company’s stock valued at $780,000 after buying an additional 182,816 shares during the period. Finally, State Street Corp grew its position in shares of Poseida Therapeutics by 48.8% in the first quarter. State Street Corp now owns 234,467 shares of the company’s stock valued at $722,000 after purchasing an additional 76,900 shares in the last quarter. Institutional investors own 50.79% of the company’s stock.
Poseida Therapeutics Company Profile
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
Read More
- Five stocks we like better than Poseida Therapeutics
- Contrarian Play: Beyond Meat Is At An Inflection Point
- Alibaba Just Flashed Green, Very Green
- This Small Cap Stock Surged Over 100%
- The CPI Data Isn’t As Good As You Think It Is
- How to Invest in Gold and Silver
Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
